Bronstein, Gewirtz & Grossman, LLC, a top firm, announces

Bronstein, Gewirtz & Grossman, LLC, a top firm, announces


NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is notifying investors that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (“Centessa” or the “Company”) ( NASDAQ: CNTA) and certain of its officers on behalf of all persons and entities that have purchased or otherwise acquired: (a) Centessa American Depositary Shares (“ADSs”) pursuant to and/or traceable to the issued Offering Documents (defined below). in connection with the Company’s initial public offering, which took place on or about May 28, 2021 (the “IPO” or the “Offering”); and/or (b) Centessa Securities between 28 May 2021 and 1 June 2022, both dates inclusive (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website:

This class action seeks damages against the defendants for alleged violations of the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that the offering documents were negligently prepared and, as a result, contained untrue statements about material facts or failed to state other facts necessary for the statements made not to be misleading and that they were not in accordance with the Rules and rules for their creation have been drawn up . In addition, the Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements about the Company’s business, operations and prospects, and particularly the Offering Documents, and Defendants made false and/or misleading statements and/or have failed to disclose that: (1) lixivaptan was less safe than defendants claimed; (2) Defendants have overstated the clinical and commercial prospects of lixivaptan; (3) ZF874 was less safe than defendants had argued; (4) Defendants have overstated ZF874’s clinical and commercial prospects while downplaying the drug’s safety issues; …

Continue to read on GlobeNewswire

More to explorer